Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1997
Key Event: On April 8, 1997, the Company completed a tax-free stock-for-stock merger with Target Therapeutics, Inc. (Target), accounted for as a pooling-of-interests. Financial statements for all periods presented have been restated to reflect this combination.
Key Financial Metrics
| Metric | Q2 1997 | Q2 1996 | 6 Months 1997 | 6 Months 1996 |
|---|---|---|---|---|
| Net Sales | $473.7 million | $379.2 million | $904.3 million | $722.8 million |
| Gross Profit Margin | 72.3% | 73.3% | 72.1% | 73.3% |
| Operating Income (Loss) | $(19.0) million | $42.0 million | $93.9 million | $80.7 million |
| Net Income (Loss) | $(26.9) million | $13.1 million | $48.5 million | $15.3 million |
| Diluted EPS | $(0.14) | $0.07 | $0.25 | $0.08 |
| Cash & Equivalents | $54.1 million | $61.2 million | $54.1 million | $61.2 million |
| Working Capital | $235.7 million | $335.0 million | $235.7 million | $335.0 million |
| Debt (Current Borrowings) | $350.3 million | $240.6 million | $350.3 million | $240.6 million |
Note: Debt figures represent borrowings due within one year, primarily commercial paper. Total funded debt capacity was increased to $500 million in June 1997.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 25% year-over-year for both the quarter and the six-month period. Organic growth (excluding currency impacts) was approximately 28%.
- Special Charges: The Company recorded $157.8 million in special charges for the quarter and six months ended June 30, 1997. This includes $96 million for estimated integration costs related to the Target merger, $16 million in transaction costs, and $12 million for purchased R&D. These charges resulted in a net loss for the quarter despite strong operating performance.
- Adjusted Performance: Excluding special charges, net income for the quarter was $90 million (up 22% from $74 million in Q2 1996). For the six-month period, adjusted net income was $166 million (up 16% from $143 million).
- Margin Compression: Gross margin decreased slightly (73.3% to 72.3% for the quarter) due to product mix shifts, pricing pressure from healthcare cost containment, and inventory build-up for new distribution centers and product launches.
- Liquidity: Cash and marketable securities declined from $118 million to $86 million due to stock repurchases ($81 million in Q2), capital expenditures ($109.6 million for six months), and merger-related costs.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Cost Structure: Management notes that operating expenses were accelerated in 1996 to prepare for 1997 growth. The elevated cost structure has not yet been fully absorbed by revenue growth, and management expects it will take several quarters to earn off these costs.
- Capital Expenditures: The Company expects to incur $100 million to $150 million in capital expenditures for the remainder of 1997, focused on manufacturing/distribution expansion and a global information system.
- Integration Costs: Cash outlays to complete integration initiatives for business combinations since 1994 are estimated at approximately $118 million, with most plans expected to be completed by the end of 1998.
Risks and Contingencies
- Patent Litigation: The Company is involved in numerous patent infringement lawsuits (e.g., against C.R. Bard, SCIMED, Cordis, Johnson & Johnson). A jury recently awarded C.R. Bard $10.8 million in damages regarding the MaxForce TTS catheter; the Company intends to appeal. Adverse outcomes could materially affect financial condition.
- Market Pressures: Continued consolidation among healthcare providers and managed care trends may result in continued pressure on selling prices and gross margins.
- Foreign Exchange: International sales (43% of total) expose the Company to currency fluctuations, though hedging strategies are in place.
Investor Verification Checklist
- Merger Integration Costs: Verify the accuracy of the $96 million estimated integration cost accrual and the timeline for cash outlays.
- Patent Litigation Exposure: Review the status of the C.R. Bard appeal and the potential financial impact of pending suits involving SCIMED, Cordis, and Johnson & Johnson.
- Inventory Levels: Assess the $306.6 million inventory balance (up from $236.7 million) and the adequacy of reserves given the shift in product mix and new distribution center openings.
- Debt Covenants: Confirm compliance with the new $500 million credit agreement covenants regarding the ratio of funded debt to tangible net worth.
- Stock Repurchase Program: Monitor the remaining capacity of the 20 million share repurchase authorization and the impact of put option obligations ($7 million contingent liability).